Skip to main content Back to Top
Advertisement

11/20/2019

Chlordiazepoxide Capsules

Products Affected - Description

    • Chlordiazepoxide capsule, Mylan Institutional, 25 mg, unit-dose blister pack, 100 count, NDC 51079-0141-20
    • Chlordiazepoxide capsule, Mylan Institutional, 5 mg, unit-dose blister pack, 100 count, NDC 51079-0374-20
    • Chlordiazepoxide capsule, Teva, 25 mg, bottle, 100 count, NDC 00555-0159-02
    • Chlordiazepoxide capsule, Teva, 25 mg, bottle, 500 count, NDC 00555-0159-04
    • Chlordiazepoxide capsule, Teva, 5 mg, bottle, 500 count, NDC 00555-0158-04

Reason for the Shortage

    • Mylan did not provide a reason for the shortage.
    • Teva did not provide a reason for the shortage.

Available Products

    • Chlordiazepoxide capsule, Mylan Institutional, 10 mg, unit-dose blister pack, 100 count, NDC 51079-0375-20
    • Chlordiazepoxide capsule, Teva, 10 mg, bottle, 100 count, NDC 00555-0033-02
    • Chlordiazepoxide capsule, Teva, 10 mg, bottle, 500 count, NDC 00555-0033-05
    • Chlordiazepoxide capsule, Teva, 5 mg, bottle, 100 count, NDC 00555-0158-02

Estimated Resupply Dates

    • Mylan Institutional has chlordiazepoxide 5 mg and 25 mg capsules in 100 count bottles on back order and the company estimates a release date of early-December 2019 for the 25 mg capsules and early-January 2020 for the 5 mg capsules.
    • Teva has chlordiazepoxide 5 mg and 25 mg capsules in 500 count bottles and 25 mg capsules in 100 count bottles on back order and the company estimates a release date of mid-December 2019.

Updated

Created November 20, 2019 by Rachael Freeman, PharmD, BCPS. © 2019, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins